澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

RADIOPHARM THERANOSTICS LTD

0.007

-0.001-12.50%

成交量：107.53萬

成交額：7,583

市值：3,036.28萬

市盈率：-0.39

高：0.008

開：0.008

低：0.007

收：0.008

52周最高：0.040

52周最低：0.007

股本：43.38億

流通股本：33.43億

量比：0.17

換手率：0.03%

股息：- -

股息率：- -

每股收益(TTM):-0.018

每股收益(LYR):-0.018

淨資產收益率：-174.71%

總資產收益率：-44.61%

市淨率：1.23

市盈率(LYR):-0.39

資料載入中...

總覽公司新聞資訊公告

Radiopharm Theranostics：所有可評估胰腺癌患者均觀察到顯著腫瘤攝取

Radiopharm Theranostics：Rad301受試者安全性良好，生物分佈表現積極

Radiopharm Theranostics公布Rad301在胰腺導管腺癌患者中的I期影像試驗積極數據

Radiopharm Theranostics年度初步虧損擴大50.3% 截至2026年6月30日財年虧損達5515萬澳元

Radiopharm Theranostics啓動Betabart（Rv-01）治療B7-H3陽性實體瘤1/2a期臨床試驗第二隊列首例患者給藥

Radiopharm Theranostics公司Rad202研究獲臨床概念驗證安全性與生物分佈數據積極

Radiopharm Theranostics獲數據安全監查委員會積極推薦，177Lu-Rad202一期HEAT臨床試驗推進至第4隊列

Radiopharm Theranostics：推進RAD202一期臨床試驗至180Mci劑量，針對HER2陽性晚期實體瘤

Radiopharm Theranostics定於2026年10月1日召開FDA二期結束會議，為Rad101三期試驗鋪路

Radiopharm Theranostics同步推進410萬美元註冊直接發行與最高1270萬澳元（約合890萬美元）澳大利亞配售及購股計劃

Radiopharm Theranostics在Rad204針對免疫療法後晚期實體瘤患者的1期試驗中獲得確認的持久部分緩解

Radiopharm Theranostics旗下Rad101在六個月隨訪中展現86%初步靈敏度；特異性數據預計2026年第四季度公布

Radiopharm Theranostics公布腦轉移診斷藥物Rad 101二期B階段試驗積極結果

Radiopharm Theranostics完成美國Rad 101診斷腦轉移瘤IIb期影像學試驗患者入組

Radiopharm Theranostics與西門子醫療簽署Rad101在美國的臨床供應協議

RADIOPHARM THERANOSTICS LTD：在晚期前列腺癌Rad 402一期臨床研究中完成首例患者給藥

RADIOPHARM THERANOSTICS LTD在腦轉移瘤Rad 101二期B階段成像試驗二次中期分析中實現90%患者主要終點指標

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/RAD.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.007,"timestamp":1789523814194,"preClose":0.008,"halted":0,"volume":1075335,"delay":0,"changeRate":-0.125,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4337549000,"eps":-0.0179,"marketStatus":"交易中","change":-0.001,"latestTime":"09-16 11:56:54 AEST","open":0.008,"high":0.008,"low":0.007,"amount":7583,"amplitude":0.125,"askPrice":0.008,"askSize":4916584,"bidPrice":0.007,"bidSize":6815658,"shortable":3,"etf":0,"ttmEps":-0.0179,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789538400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.008,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.174136,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.008,"auctionPrice":0.008,"auctionVolume":55666,"auctionTime":1789516742732,"referenceTime":1789468203091,"auction":1,"marketStatus":"盘前竞价","timestamp":1789516742732}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-44.61%","roe":"-174.71%","lyrEps":-0.0179,"volumeRatio":0.174136,"shares":4337549000,"dividePrice":0,"high":0.008,"amplitude":0.125,"preClose":0.008,"low":0.007,"week52Low":0.007,"pbRate":"1.23","psRate":"2.25","week52High":0.04,"institutionHeld":0,"latestPrice":0.007,"committee":0.161868,"eps":-0.0179,"divideRate":0,"volume":1075335,"delay":0,"ttmEps":-0.0179,"open":0.008,"prevYearClose":0.025,"prevWeekClose":0.008,"prevMonthClose":0.01,"prevQuarterClose":0.019,"fiveDayClose":0.009,"twentyDayClose":0.012,"sixtyDayClose":0.019,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1106926898","title":"Radiopharm Theranostics：所有可評估胰腺癌患者均觀察到顯著腫瘤攝取","url":"https://stock-news.laohu8.com/highlight/detail?id=1106926898","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106926898?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:11","pubTimestamp":1788952276,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics传来重磅消息——在其相关研究中，所有可评估的胰腺癌患者均表现出了显著的肿瘤摄取现象。这一发现无疑为胰腺癌诊疗领域投下了一枚震撼弹。据悉，该结果可能为后续更精准的靶向治疗与成像策略奠定关键基础，其临床意义不容小觑。业界普遍关注，这一积极信号能否顺利转化为切实可行的治疗方案，从而惠及广大患者群体。市场对此消息的初步反应亦颇为敏感，投资者正密切观望后续的详细数据披露与监管审批动向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124219327","title":"Radiopharm Theranostics：Rad301受試者安全性良好，生物分佈表現積極","url":"https://stock-news.laohu8.com/highlight/detail?id=1124219327","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124219327?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:11","pubTimestamp":1788952273,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司宣布，其候选药物Rad301在临床试验中展现出令人鼓舞的结果。所有接受该药物剂量给药的研究对象均表现出良好的安全性，同时生物分布数据也呈现有利态势。这一积极进展为公司研发管线注入了新的信心，Rad301作为潜在治疗方案的可行性与耐受性获得了初步验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141615521","title":"Radiopharm Theranostics公布Rad301在胰腺導管腺癌患者中的I期影像試驗積極數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1141615521","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141615521?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:02","pubTimestamp":1788951758,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics今日宣布，其候选药物Rad301在针对胰腺导管腺癌患者的I期影像学临床试验中取得了令人振奋的积极结果。这一进展为该公司在肿瘤精准诊断领域的布局注入了新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172086213","title":"Radiopharm Theranostics年度初步虧損擴大50.3% 截至2026年6月30日財年虧損達5515萬澳元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172086213","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172086213?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 14:10","pubTimestamp":1787897411,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics（澳大利亚证券交易所代码：RAD.AU）披露了截至2026年6月30日的年度初步财务业绩，数据显示该公司年度应占亏损同比扩大50.3%，达到5515万澳元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191690899","title":"Radiopharm Theranostics啓動Betabart（Rv-01）治療B7-H3陽性實體瘤1/2a期臨床試驗第二隊列首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1191690899","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191690899?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 19:03","pubTimestamp":1787742188,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司宣布，其针对B7-H3阳性实体瘤的候选药物Betabart在1/2a期临床试验中，已顺利完成第二队列首例患者的给药。Betabart作为一种靶向B7-H3的放射性治疗药物，其设计理念在于将放射性同位素精准递送至肿瘤细胞表面高表达的B7-H3抗原，从而实现针对性的杀伤效果，同时尽可能减少对周围正常组织的损伤。B7-H3在多种实体瘤中广泛表达，与肿瘤的发生发展及不良预后密切相关，因此成为癌症治疗领域备受关注的热门靶点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119579747","title":"Radiopharm Theranostics公司Rad202研究獲臨床概念驗證 安全性與生物分佈數據積極","url":"https://stock-news.laohu8.com/highlight/detail?id=1119579747","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119579747?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 19:02","pubTimestamp":1787223725,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司公布了一项关于其候选药物Rad202的最新研究成果。该研究结果标志着该药物在临床试验中取得了重要的概念验证，其安全性和生物分布方面的表现均呈现积极态势。具体而言，这项研究为Rad202的后续开发奠定了坚实基础。它不仅验证了Rad202的科学原理，也进一步增强了市场对公司研发管线和整体技术平台的信心。公司认为，这一进展将有助于推动该候选药物进入下一阶段的临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171695853","title":"Radiopharm Theranostics獲數據安全監查委員會積極推薦，177Lu-Rad202一期HEAT臨床試驗推進至第4隊列","url":"https://stock-news.laohu8.com/highlight/detail?id=1171695853","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171695853?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 19:01","pubTimestamp":1787223679,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics宣布，其数据安全监查委员会已给出积极推荐意见，同意177Lu-Rad202一期HEAT临床试验向前推进至第4队列。这一关键进展标志着该研究项目迈入新的阶段，为后续研发铺平了道路。委员会基于现有数据的安全性和可行性评估，作出了支持继续推进的决定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192885524","title":"Radiopharm Theranostics：推進RAD202一期臨床試驗至180Mci劑量，針對HER2陽性晚期實體瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1192885524","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192885524?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 19:01","pubTimestamp":1787223676,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics宣布，其RAD202一期临床试验已推进至180Mci剂量水平，该试验针对HER2阳性晚期实体瘤患者。这一进展标志着公司在放射性药物开发领域的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107926876","title":"Radiopharm Theranostics定於2026年10月1日召開FDA二期結束會議，為Rad101三期試驗鋪路","url":"https://stock-news.laohu8.com/highlight/detail?id=1107926876","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107926876?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:31","pubTimestamp":1786966268,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司已正式敲定，将于2026年10月1日与美国食品药品监督管理局（FDA）举行一场关键的二期结束会议。此次会议的核心议题，是围绕其备受瞩目的Rad101药物所即将启动的三期临床试验展开深入磋商与交流。这一重要日程的安排，标志着该公司在推进其放射性药物管线进程中，又迈出了具有战略意义的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183705268","title":"Radiopharm Theranostics同步推進410萬美元註冊直接發行與最高1270萬澳元（約合890萬美元）澳大利亞配售及購股計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1183705268","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183705268?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 19:16","pubTimestamp":1784891770,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics宣布了一项重大融资举措：同步启动410万美元的注册直接发行，并计划在澳大利亚进行最高1270万澳元（约合890万美元）的配售及购股计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153196759","title":"Radiopharm Theranostics在Rad204針對免疫療法後晚期實體瘤患者的1期試驗中獲得確認的持久部分緩解","url":"https://stock-news.laohu8.com/highlight/detail?id=1153196759","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153196759?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 19:06","pubTimestamp":1784718381,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics在其正在进行的Rad204药物1期临床试验中取得积极进展。该试验针对既往接受过免疫疗法但病情仍出现进展的晚期实体瘤患者，目前已观察到获得确认的持久性部分缓解的病例。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194417652","title":"Radiopharm Theranostics旗下Rad101在六個月隨訪中展現86%初步靈敏度；特異性數據預計2026年第四季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1194417652","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194417652?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 19:03","pubTimestamp":1784718195,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd (ASX: RAD) 公布了其放射性药物候选产品Rad101的最新临床数据，该产品在为期六个月的随访中显示出高达86%的初步灵敏度。此项积极结果标志着该疗法在诊断应用领域取得了重要进展。\n公司预计，关于Rad101的特异性关键数据将于2026年第四季度对外公布。特异性数据的出炉，将为进一步评估该药物的整体诊断效能提供至关重要的补充信息，从而为未来的临床开发与潜在应用奠定更坚实的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127955453","title":"Radiopharm Theranostics公布腦轉移診斷藥物Rad 101二期B階段試驗積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1127955453","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127955453?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 19:01","pubTimestamp":1784718075,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics宣布其用于诊断脑转移的候选药物Rad 101，在二期B阶段临床试验中取得了积极成果。该试验结果标志着公司在精准肿瘤诊断领域取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123883160","title":"Radiopharm Theranostics完成美國Rad 101診斷腦轉移瘤IIb期影像學試驗患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=1123883160","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123883160?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 19:01","pubTimestamp":1776337312,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd (RAD.AU) 宣布已顺利完成其在美国开展的Rad 101诊断脑转移瘤IIb期影像学试验的患者招募工作。该试验旨在评估Rad 101在脑转移瘤诊断中的应用效果，标志着公司在核医学诊疗领域取得重要阶段性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109392364","title":"Radiopharm Theranostics與西門子醫療簽署Rad101在美國的臨床供應協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1109392364","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109392364?lang=zh_tw&edition=fundamental","pubTime":"2026-04-07 19:04","pubTimestamp":1775559877,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd (ASX: RAD) 已与西门子医疗（Siemens Healthineers）正式签署一项临床供应协议，双方将围绕放射性药物Rad101在美国市场的临床供应展开合作。该协议的签署标志着两家公司在肿瘤靶向治疗领域的战略合作迈出关键一步，旨在加速Rad101的临床开发进程，为后续的临床应用奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140442862","title":"RADIOPHARM THERANOSTICS LTD：在晚期前列腺癌Rad 402一期臨床研究中完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1140442862","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140442862?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 20:12","pubTimestamp":1774613548,"startTime":"0","endTime":"0","summary":"RADIOPHARM THERANOSTICS LTD宣布，其针对晚期前列腺癌的靶向疗法Rad 402，已在一期临床研究中完成对首位患者的给药。这一里程碑标志着该创新疗法的临床开发进入新阶段，为晚期前列腺癌患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113664581","title":"RADIOPHARM THERANOSTICS LTD在腦轉移瘤Rad 101二期B階段成像試驗二次中期分析中實現90%患者主要終點指標","url":"https://stock-news.laohu8.com/highlight/detail?id=1113664581","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113664581?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 19:02","pubTimestamp":1774350158,"startTime":"0","endTime":"0","summary":"在针对脑转移瘤患者开展的Rad 101二期B阶段成像试验中，RADIOPHARM THERANOSTICS LTD于最新公布的二次中期分析数据显示，该试验已达到90%受试者的主要研究终点。这一突破性进展不仅验证了放射性药物在神经肿瘤影像学领域的应用潜力，更标志着靶向诊疗一体化技术向临床转化迈出关键一步。通过精准定位转移病灶的成像表现，该试验为后续治疗策略的制定提供了重要影像学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}